Peters S, et al. Nivolumab + low-dose ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non–small cell lung cancer: CheckMate-227 part 1 final analysis. ESMO Congress 2019, abstract LBA4.
Nivolumab-relatlimab (Opdualag) voor behandeling huidkanker niet in basispakket
mei 2024 | Dermato-oncologie, Immuuntherapie